{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:39:34Z","timestamp":1792093174871,"version":"4.4.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circ: Heart Failure"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Thiazolidinediones (rosiglitazone, pioglitazone) are oral insulin-sensitizing medications used in type 2 diabetes mellitus that reduce glucose with minimal risk of hypoglycemia and potential benefits on atherosclerosis. However, thiazolidinediones can cause fluid retention thereby increasing the risk of heart failure\u2014a common complication of type 2 diabetes mellitus.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and Results:<\/jats:title>\n                    <jats:p>Data were analyzed from the Diabetes Collaborative Registry, a US outpatient registry of patients with type 2 diabetes mellitus that currently encompasses 203 cardiology, endocrinology, and primary care practices and 3074 providers. Among 424\u2009061 US adults enrolled in Diabetes Collaborative Registry who had type 2 diabetes mellitus and were taking \u22651 glucose-lowering medication, 35\u2009018 patients (8.3%) were on a thiazolidinedione, which has remained stable over time. Patients on thiazolidinediones tended to be old (mean age, 69.2\u00b110.7 years), 61.9% had coronary disease, and 17.2% had class 3 obesity. In total, 40.3% of patients on a thiazolidinedione had either a clinical diagnosis of heart failure (23.7%), had an ejection fraction of &lt;40% (7.7%), or were on a loop diuretic (29.9%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Although thiazolidinediones lost significant market share after 2007 when concerns arose regarding their safety, thiazolidinediones are still commonly used. At least a quarter, and up to two-fifths, of patients currently treated with thiazolidinediones have some evidence of heart failure and therefore should not be candidates for this therapy. Accordingly, heart failure concerns with thiazolidinediones may be under-recognized.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/circheartfailure.118.005855","type":"journal-article","created":{"date-parts":[[2019,5,27]],"date-time":"2019-05-27T01:00:11Z","timestamp":1558918811000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":63,"title":["Understanding Contemporary Use of Thiazolidinediones"],"prefix":"10.1161","volume":"12","author":[{"given":"Suzanne V.","family":"Arnold","sequence":"first","affiliation":[{"name":"Saint Luke\u2019s Mid America Heart Institute (S.V.A., F.T., M.K.)."},{"name":"University of Missouri-Kansas City (S.V.A., F.T., M.K.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio E.","family":"Inzucchi","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, CT (S.E.I.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin B.","family":"Echouffo-Tcheugui","sequence":"additional","affiliation":[{"name":"Johns Hopkins Bayview Medical Center, Baltimore, MD (J.B.E.-T.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengming","family":"Tang","sequence":"additional","affiliation":[{"name":"Saint Luke\u2019s Mid America Heart Institute (S.V.A., F.T., M.K.)."},{"name":"University of Missouri-Kansas City (S.V.A., F.T., M.K.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S.P.","family":"Lam","sequence":"additional","affiliation":[{"name":"Duke-National University of Singapore, National Heart Centre, Singapore (C.S.P.L.)."},{"name":"University Medical Centre Groningen (C.S.P.L.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence S.","family":"Sperling","sequence":"additional","affiliation":[{"name":"Emory University School of Medicine, Atlanta, GA (L.S.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Kosiborod","sequence":"additional","affiliation":[{"name":"Saint Luke\u2019s Mid America Heart Institute (S.V.A., F.T., M.K.)."},{"name":"University of Missouri-Kansas City (S.V.A., F.T., M.K.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072761"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60953-3"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67528-9"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073394"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61514-1"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066224"},{"key":"e_1_3_3_8_2","unstructured":"US Food and Drug Administration. MedWatch the FDA Safety Information and Adverse Event Reporting Program - Avandia (rosiglitazone). https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-avandia-rosiglitazone-labels-now-contain-updated-information-about. Accessed May 9 2019."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.3810\/pgm.2012.01.2525"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.296.21.joc60158"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.299.13.1561"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506930"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.014796"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-0585"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.034763"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.005231"}],"container-title":["Circulation: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCHEARTFAILURE.118.005855","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T21:29:37Z","timestamp":1715549377000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCHEARTFAILURE.118.005855"}},"subtitle":["An Analysis From the Diabetes Collaborative Registry"],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":15,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1161\/CIRCHEARTFAILURE.118.005855"],"URL":"https:\/\/doi.org\/10.1161\/circheartfailure.118.005855","relation":{},"ISSN":["1941-3289","1941-3297"],"issn-type":[{"value":"1941-3289","type":"print"},{"value":"1941-3297","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"2019-05-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e005855"}}